AtaiBeckley (ATAI) Return on Capital Employed (2021 - 2026)
AtaiBeckley (ATAI) posted Return on Capital Employed of 187.28% for Q1 2025, down 282.03% sequentially from 49.02% in Q2 2024, and down 14359.0% YoY from N/an in Q1 2024.
AtaiBeckley (ATAI) Return on Capital Employed (2021 - 2026) Analysis & Trends
AtaiBeckley has reported Return on Capital Employed for 5 years, with the latest figure at 187.28% in Q1 2025.
- Quarterly Return on Capital Employed fell 14359.0% year-over-year to 187.28% in Q1 2025, while the trailing twelve-month figure through Mar 2025 was 187.28% (down 14359.0% YoY) and the FY2024 annual result came in at 50.97%, down 605.0% from the prior year.
- Return on Capital Employed slipped to 187.28% in Q1 2025 per ATAI's latest filing, from 49.02% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 1232.45% in Q3 2021 and troughed at 187.28% in Q1 2025.
- A 5-year average of 235.72% and a median of 47.61% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed slumped 79741 bps in 2022, then soared 924 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 749.81% in 2021, then slumped by 106 bps to 47.61% in 2022, then gained by 6 bps to 44.69% in 2023, then dropped by 10 bps to 49.02% in 2024, then slumped by 282 bps to 187.28% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 187.28%, 49.02%, and 43.69% for Q1 2025, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | AtaiBeckley | 2.69 Bn | 2.69 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -51.07% |
| Mar 31, 2025 | -187.28% |
| Jun 30, 2024 | -49.02% |
| Mar 31, 2024 | -43.69% |
| Dec 31, 2023 | -44.69% |
| Sep 30, 2023 | -49.57% |
| Jun 30, 2023 | -56.60% |
| Mar 31, 2023 | -52.93% |
| Dec 31, 2022 | -47.61% |
| Dec 31, 2021 | 749.81% |
| Sep 30, 2021 | 1,232.45% |
| Jun 30, 2021 | 1,142.05% |